-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HZ23mQ9qyKgWuIo91qfg9J/Ktt/5lmj10lnaWoGUo66CTJ7qh4z5Oxk/QkjZuagw ndUir0QKWlhsoYvk8vaPHQ== 0000899243-02-002259.txt : 20020813 0000899243-02-002259.hdr.sgml : 20020813 20020813161559 ACCESSION NUMBER: 0000899243-02-002259 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20020813 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: FILED AS OF DATE: 20020813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 02729927 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 8-K 1 d8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 13, 2002 US ONCOLOGY, INC. ----------------------------- (Exact Name of Registrant as Specified in its Charter) Delaware 0-26190 84-1213501 - ---------------- ------------ ------------------- (State or Other (Commission (I.R.S.Employer Jurisdiction of File Number) Identification No.) Incorporation or Organization) 16825 Northchase Drive, Suite 1300 Houston, Texas 77060 -------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (832) 601-8766 Item 9. REGULATION FD DISCLOSURE On August 13, 2002, R. Dale Ross, Chairman of the Board and Chief Executive Officer of US Oncology, Inc. (the "Corporation"), and Bruce D. Broussard, Chief Financial Officer of the Corporation, each filed with the Securities and Exchange Commission (the "SEC") a statement under oath regarding facts and circumstances relating to the Securities Exchange Act filings of the Corporation, as required by the SEC's Order Requiring the Filing of Sworn Statements Pursuant to Section 21(a)(1) ofthe Securities Exchange Act of 1934 (File No. 4-460, June 27, 2002). The statements are attached to this report as exhibits. Item 7. FINANCIAL STATEMENTS AND EXHIBITS c) Exhibits 99.1 STATEMENT UNDER OATH OF CHIEF EXECUTIVE OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS 99.2 STATEMENT UNDER OATH OF CHIEF FINANCIAL OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934,the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2002 US ONCOLOGY, INC. By: Bruce D. Broussard ------------------------- Bruce D. Broussard Chief Financial Officer EX-99.1 3 dex991.txt STATEMENT UNDER OATH OF CEO Exhibit 99.1 US ONCOLOGY, INC. STATEMENT UNDER OATH OF CHIEF EXECUTIVE OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS - -------------------------------------------------------- I, R. Dale Ross, Chief Executive Officer of US Oncology, Inc., state and attest that: 1. To the best of my knowledge, based upon a review of the covered reports of US Oncology, Inc., and, except as corrected or supplemented in a subsequent covered report: o no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and o no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed). 2. I have reviewed the contents of this statement with the Company's audit committee. 3. In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report": o 2001 10-K of US Oncology, Inc.; o all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of US Oncology, Inc. filed with the Commission subsequent to the filing of the Form 10-K identified above; and o any amendments to any of the foregoing. /s/ R. Dale Ross Date: August 13, 2002 - --------------------------------------------- R. Dale Ross Chief Executive Officer STATE OF TEXAS COUNTY OF HARRIS SUBSCRIBED AND sworn to before me on this 13th day of August, 2002. /s/ Alice Cole Wright Notary Public My Commission Expires: April 24, 2005 (seal) EX-99.2 4 dex992.txt STATEMENT UNDER OATH OF CFO Exhibit 99.2 US ONCOLOGY, INC. STATEMENT UNDER OATH OF CHIEF FINANCIAL OFFICER REGARDING FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS - -------------------------------------------------------- I, Bruce D. Broussard, Chief Financial Officer of US Oncology, Inc., state and attest that: 4. To the best of my knowledge, based upon a review of the covered reports of US Oncology, Inc., and, except as corrected or supplemented in a subsequent covered report: o no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and o no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed). 5. I have reviewed the contents of this statement with the Company's audit committee. 6. In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report": o 2001 10-K of US Oncology, Inc.; o all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of US Oncology, Inc. filed with the Commission subsequent to the filing of the Form 10-K identified above; and o any amendments to any of the foregoing. /s/ Bruce D. Broussard Date: August 13, 2002 - -------------------------------------------------- Bruce D. Broussard Chief Financial Officer STATE OF TEXAS COUNTY OF HARRIS SUBSCRIBED AND sworn to before me on this 13th day of August, 2002. /s/ Teresa M. Pruitt Notary Public My Commission Expires: September 21, 2002 (seal) -----END PRIVACY-ENHANCED MESSAGE-----